Striatal dopamine transporter imaging in Parkinson’s disease drug-naïve patients: focus on sexual dysfunction
Objective: To evaluate whether the 123I-FP-CIT striatal uptake differs in Parkinson’s disease (PD) drug-naïve patients with and without sexual dysfunction. Background: Sexual dysfunction is one…Disease progression characterized by motor performance, dopaminergic neurodegeneration and T cell infiltration in the transgenic hm2-α-SYN-39 mouse model of Parkinson´s disease
Objective: To study disease progression in the transgenic (tg) hm2-α-SYN-39 mouse model of Parkinson´s disease (PD) by assessment of motor performance, dopaminergic neurodegeneration and T…Probabilistic tractography study of the nigrostriatal pathway in Parkinson’s disease
Objective: To investigate changes in connectivity of the nigrostriatal and striatonigral pathways in PD and association with clinical symptoms. Background: Loss of dopaminergic neurons in…To compare early / late onset MSA from the PAN American MSA (PANMSA) database
Objective: Compare two different cohorts of patients with the same pathology differentiated by age of onset. Background: Multiple system atrophy (MSA) is a rare neurodegenerative…PPMI driven sample size estimation for clinical trials in Parkinson’s disease
Objective: To utilize clinical, imaging and CSF data from the Parkinson’s Progression Markers Initiative (PPMI) to estimate the sample size for disease modification studies in…Remote patient monitoring with a digital biomarker approach generates clinically distinctive and meaningful sensor feature data in Parkinson’s disease: Differential relationships with MDS-UPDRS-III, PDQ-39 and DaT-SPECT
Objective: To determine whether sensor features derived from remote smartphone testing in Parkinson’s disease (PD) predicted clinical, quality of life and biomarker measures collected in…Predictors and biomarkers of pain in newly diagnosed Parkinson’s disease patients during a two-year follow-up
Objective: To identify clinical characteristics, predictors and biomarkers of pain at baseline and after a two-year follow-up period in newly diagnosed drug-naïve Parkinson's Disease (PD)…α-synuclein aggregation and propagation in marmoset brains deteriorates its motor function
Objective: To confirm that α-synuclein aggregation and propagation in marmoset brains deteriorates its motor function. Background: Recently, the α-synuclein amyloid fibril is thought to be…Clinical and Imaging and phenoconversion in the PARS prodromal cohort
Objective: We report clinical and imaging phenoconversion data at 6 years follow-up for the PARS cohort. Background: The PARS cohort consists of 203 hyposmic and…Optimization of 6-hydroxydopamine animal model of early stage Parkinson´s disease for the assessment of neurorestorative therapies
Objective: To optimize a simple unilateral partial 6-hydroxydopamine (6-OHDA) lesion protocol that would produce 40-60% striatal dopamine (DA) depletion with detectable motor deficits and to…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.